Clinics in Dermatology
Volume 27, Issue 1 , Pages 53-74 , January 2009

Melanoma prognostic factors found in the dermatopathology report

References 

  1. Balzi D, Carli P, Giannotti B, et al. Skin melanoma in Italy: a population-based study on survival and prognostic factors. Eur J Cancer. 1998;34:699–704
  2. Lindholm C, Andersson R, Dufmats M, et al. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer. 2004;101:2067–2078
  3. Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol. 1994;1:487–494
  4. Chao C, Martin RC, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11:259–264
  5. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics. 2005;115:649–654
  6. Sander B, Karlsson P, Rosdahl I, et al. Cutaneous malignant melanoma in Swedish children and teenagers 1973-1992: a clinico-pathological study of 130 cases. Int J Cancer. 1999;80:646–651
  7. Reintgen DS, Vollmer R, Seigler HF. Juvenile malignant melanoma. Surg Gynecol Obstet. 1989;168:249–253
  8. Cochran AJ, Elashoff D, Morton DL, et al. Individualized prognosis for melanoma patients. Hum Pathol. 2000;31:327–331
  9. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995;75:2484–2491
  10. Karakousis CP, Driscoll DL. Prognostic parameters in localised melanoma: gender versus anatomical location. Eur J Cancer. 1995;31A:320–324
  11. Levi F, Randimbison L, La Vecchia C, et al. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer. 1998;78:315–319
  12. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426–433
  13. Masback A, Olsson H, Westerdahl J, et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res. 2001;11:435–445
  14. Ilmonen S, Asko-Seljavaara S, Kariniemi AL, et al. Prognosis of primary melanoma. Scand J Surg. 2002;91:166–171
  15. Hsueh EC, Lucci A, Qi K, et al. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer. 1999;85:383–388
  16. Talley LI, Soong S, Harrison RA, et al. Clinical outcomes of localized melanoma of the foot: a case-control study. J Clin Epidemiol. 1998;51:853–857
  17. Barnes BC, Seigler HF, Saxby TS, et al. Melanoma of the foot. J Bone Joint Surg Am. 1994;76:892–898
  18. Gillgren P, Mansson-Brahme E, Frisell J, et al. A prospective population-based study of cutaneous malignant melanoma of the head and neck. Laryngoscope. 2000;110:1498–1504
  19. Wanebo HJ, Cooper PH, Young DV, et al. Prognostic factors in head and neck melanoma. Effect of lesion location. Cancer. 1988;62:831–837
  20. Lachiewicz AM, Berwick M, Wiggins CL, et al. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008;144:515–521
  21. Leong SP, Accortt NA, Essner R, et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006;132:370–373
  22. Benmeir P, Baruchin A, Lusthaus S, et al. Melanoma of the scalp: the invisible killer. Plast Reconstr Surg. 1995;95:496–500
  23. Shumate CR, Carlson GW, Giacco GG, et al. The prognostic implications of location for scalp melanoma. Am J Surg. 1991;162:315–319
  24. Nagore E, Oliver V, Botella-Estrada R, et al. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res. 2005;15:169–177
  25. Law MM, Wong JH. Evaluation of the prognostic significance of the site of origin of cutaneous melanoma. Am Surg. 1994;60:362–366
  26. Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol. 2006;155:771–777
  27. Gillgren P, Brattstrom G, Frisell J, et al. Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations. Melanoma Res. 2005;15:125–132
  28. MacKie RM, Hole D, Hunter JA, et al. Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. BMJ. 1997;315:1117–1121
  29. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668–3676
  30. Leiter U, Buettner PG, Eigentler TK, et al. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. J Clin Oncol. 2004;22:3660–3667
  31. McKinnon JG, Yu XQ, McCarthy WH, et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223–1231
  32. Zalaudek I, Horn M, Richtig E, et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol. 2003;148:703–708
  33. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–908
  34. Crowson AN, Magro CM, Mihm MC. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol. 2006;19(Suppl 2):S71–S87
  35. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg. 1975;182:572–575
  36. Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427–432
  37. Rousseau DL, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569–574
  38. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  39. Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732–742
  40. McGovern VJ, Shaw HM, Milton GW, et al. Prognostic significance of the histological features of malignant melanoma. Histopathology. 1979;3:385–393
  41. Day CL, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery. 1981;89:599–603
  42. Day CL, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. Am J Surg. 1981;142:247–251
  43. Van Der Esch EP, Cascinelli N, Preda F, et al. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer. 1981;48:1668–1673
  44. Drzewiecki KT, Andersen PK. Survival with malignant melanoma: a regression analysis of prognostic factors. Cancer. 1982;49:2414–2419
  45. Prade M, Bognel C, Charpentier P, et al. Malignant melanoma of the skin: prognostic factors derived from a multifactorial analysis of 239 cases. Am J Dermatopathol. 1982;4:411–412
  46. Day CL, Mihm MC, Lew RA, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg. 1982;195:35–43
  47. Kuehnl-Petzoldt C, Wiebelt H, Berger H. Prognostic groups of patients with stage I melanoma. Arch Dermatol. 1983;119:816–819
  48. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982;196:677–684
  49. Urist MM, Balch CM, Soong SJ, et al. Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg. 1984;200:769–775
  50. Cascinelli N, Marubini E, Morabito A, et al. Prognostic factors for stage I melanoma of the skin: a review. Stat Med. 1985;4:265–278
  51. Shaw HM, Balch CM, Soong SJ, et al. Prognostic histopathological factors in malignant melanoma. Pathology. 1985;17:271–274
  52. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. A multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol. 1985;406:179–195
  53. Meyskens FL, Berdeaux DH, Parks B, et al. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer. 1988;62:1207–1214
  54. Ronan SG, Han MC, Das Gupta TK. Histologic prognostic indicators in cutaneous malignant melanoma. Semin Oncol. 1988;15:558–565
  55. Clark WH, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893–1904
  56. Vollmer RT. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Annu. 1989;24(Pt 1):383–407
  57. Worth AJ, Gallagher RP, Elwood JM, et al. Pathologic prognostic factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Int J Cancer. 1989;43:370–375
  58. Heenan PJ, English DR, Holman CD, et al. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/1981. Cancer. 1991;68:2079–2087
  59. Haffner AC, Garbe C, Burg G, et al. The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer. 1992;66:856–861
  60. Soong SJ, Shaw HM, Balch CM, et al. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg. 1992;16:191–195
  61. Straume O, Akslen LA. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1996;78:1211–1219
  62. Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer. 1997;80:1426–1431
  63. Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67:228–233
  64. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
  65. Haddad FF, Stall A, Messina J, et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol. 1999;6:144–149
  66. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97
  67. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000;89:453–462
  68. Zettersten E, Shaikh L, Ramirez R, et al. Prognostic factors in primary cutaneous melanoma. Surg Clin North Am. 2003;83:61–75
  69. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  70. Karakousis CP, Emrich LJ, Rao U. Tumor thickness and prognosis in clinical stage I malignant melanoma. Cancer. 1989;64:1432–1436
  71. Slingluff CL, Vollmer RT, Reintgen DS, et al. Lethal “thin” malignant melanoma. Identifying patients at risk. Ann Surg. 1988;208:150–161
  72. Clark WH, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–727
  73. Morton DL, Davtyan DG, Wanek LA, et al. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer. 1993;71:3737–3743
  74. Thorn M, Bergstrom R, Hedblad M, et al. Predictors of late mortality in cutaneous malignant melanoma-a population-based study in Sweden. Int J Cancer. 1996;67:38–44
  75. Marghoob AA, Koenig K, Bittencourt FV, et al. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer. 2000;88:589–595
  76. Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer. 1995;75:2499–2506
  77. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039–1051
  78. Slingluff CL, Seigler HF. “Thin” malignant melanoma: risk factors and clinical management. Ann Plast Surg. 1992;28:89–94
  79. Pontikes LA, Temple WJ, Cassar SL, et al. Influence of level and depth on recurrence rate in thin melanomas. Am J Surg. 1993;165:225–228
  80. Smolle J, Okcu A, Hofmann-Wellenhof R, et al. Automated measurement of melanoma cross-sectional area. Am J Dermatopathol. 1998;20:155–159
  81. Temple CF, Huchcroft SA, Hurlbut DJ, et al. Histologic staging in malignant melanoma: cross-sectional area revisited. J Surg Oncol. 1998;69:83–87
  82. Friedman RJ, Rigel DS, Kopf AW, et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator. Preliminary observation. Dermatol Clin. 1991;9:643–648
  83. Gebhart W, Knobler R. Computer-assisted volumetric analysis of cutaneous malignant melanomas. Am J Dermatopathol. 1984;6(Suppl):93–95
  84. Rongioletti F, Smoller BR. Unusual histological variants of cutaneous malignant melanoma with some clinical and possible prognostic correlations. J Cutan Pathol. 2005;32:589–603
  85. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 4. The relation of cross-sectional profile, level of invasion, ulceration and vascular invasion to tumour type and prognosis. Acta Pathol Microbiol Scand [A]. 1979;87A:131–138
  86. Siminovitch JM, Bergfeld W, Dinner M. Exophytic (pedunculated) malignant melanoma-Cleveland Clinic experience. Ann Plast Surg. 1980;5:432–435
  87. Manci EA, Balch CM, Murad TM, et al. Polypoid melanoma, a virulent variant of the nodular growth pattern. Am J Clin Pathol. 1981;75:810–815
  88. Kuehnl-Petzoldt C, Berger H, Wiebelt H. Verrucous-keratotic variations of malignant melanoma: a clinicopathological study. Am J Dermatopathol. 1982;4:403–410
  89. Beardmore GL, Quinn RL, Little JH. Malignant melanoma in Queensland: pathology of 105 fatal cutaneous melanomas. Pathology. 1970;2:277–286
  90. Liestol K, Larsen TE, Grude TH. A Retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 8. The Relative prognostic value of various clinical and histological features evaluated by Cox’s regression model. Acta Pathol Microbiol Immunol Scand [A]. 1982;90:449–454
  91. Corona R, Scio M, Mele A, et al. Survival and prognostic factors in patients with localised cutaneous melanoma observed between 1980 and 1991 at the Istituto Dermopatico dell’Immacolata in Rome, Italy. Eur J Cancer. 1994;30A:333–338
  92. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998;5:322–328
  93. Berdeaux DH, Meyskens FL, Parks B, et al. Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease. Cancer. 1989;63:1430–1436
  94. Retsas S, Henry K, Mohammed MQ, et al. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer. 2002;38:511–516
  95. Gordon LG, Lowry WS, Pedlow PJ, et al. Poor prognosis for malignant melanoma in Northern Ireland: a multivariate analysis. Br J Cancer. 1991;63:283–286
  96. Lassau N, Koscielny S, Avril MF, et al. Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of melanomas. AJR Am J Roentgenol. 2002;178:1547–1551
  97. Masback A, Westerdahl J, Ingvar C, et al. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations. Cancer. 1997;79:275–283
  98. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012–3017
  99. Kim SH, Garcia C, Rodriguez J, et al. Prognosis of thick cutaneous melanoma. J Am Coll Surg. 1999;188:241–247
  100. Zettersten E, Sagebiel RW, Miller JR, et al. Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer. 2002;94:1049–1056
  101. Otto FJ, Goldmann T, Biess B, et al. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters. Oncology. 1999;56:208–214
  102. Cuellar FA, Vilalta A, Rull R, et al. Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res. 2004;14:277–282
  103. Glass LF, Guffey JM, Schroer KR, et al. Histopathologic study of recurrent Clark level II melanomas. Semin Surg Oncol. 1993;9:202–207
  104. Chang CK, Jacobs IA, Vizgirda VM, et al. Melanoma in the elderly patient. Arch Surg. 2003;138:1135–1138
  105. Chang CK, Jacobs IA, Theodosiou E, et al. Thick melanoma in the elderly. Am Surg. 2003;69:988–993
  106. Grande Sarpa H, Reinke K, Shaikh L, et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol. 2006;30:1396–1400
  107. Schmid-Wendtner MH, Baumert J, Schmidt M, et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res. 2001;11:619–626
  108. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488–1498
  109. Barnhill RL, Katzen J, Spatz A, et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268–273
  110. Smolle J, Hofmann-Wellenhof R, Kofler R, et al. Tumor cell proliferation and motility estimates are prognostic factors in malignant melanoma. Anal Cell Pathol. 1993;5:113–124
  111. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol. 2002;20:1826–1831
  112. Fortes C, Mastroeni S, Sera F, et al. Survival and prognostic variables of cutaneous melanoma observed between 1995 and 2000 at Istituto Dermopatico Dell’Immacolata (IDI-IRCCS), Rome, Italy. Eur J Cancer Prev. 2006;15:171–177
  113. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol. 2007;127:380–384
  114. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001;137:1169–1173
  115. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol. 1978;114:871–873
  116. Kopf AW, Gross DF, Rogers GS, et al. Prognostic index for malignant melanoma. Cancer. 1987;59:1236–1241
  117. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003;36:347–350
  118. Lefevre M, Vergier B, Balme B, et al. Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol. 2003;27:717–724
  119. Mansson-Brahme E, Carstensen J, Erhardt K, et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer. 1994;73:2324–2332
  120. Paladugu RR, Yonemoto RH. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983;118:41–44
  121. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. Virchows Arch A Pathol Anat Histopathol. 1985;408:241–247
  122. Ronan SG, Eng AM, Briele HA, et al. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123:1326–1330
  123. Shaw HM, Rivers JK, McCarthy SW, et al. Cutaneous melanomas exhibiting unusual biologic behavior. World J Surg. 1992;16:196–202
  124. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603–608
  125. Trau H, Rigel DS, Harris MN, et al. Metastases of thin melanomas. Cancer. 1983;51:553–556
  126. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer. 1985;56:2287–2291
  127. Briggs JC, Ibrahim NB, Hastings AG, et al. Experience of thin cutaneous melanomas (less than 0.76 mm and less than 0.85 mm thick) in a large plastic surgery unit: a 5 to 17 year follow-up. Br J Plast Surg. 1984;37:501–506
  128. Cooper PH, Wanebo HJ, Hagar RW. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol. 1985;121:1127–1131
  129. Brogelli L, Reali UM, Moretti S, et al. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res. 1992;2:87–91
  130. McCarthy WH, Shaw HM, McCarthy SW, et al. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol. 1996;23:709–713
  131. Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303–1310
  132. Cecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol. 2007;34:512–515
  133. Kaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61:297–300
  134. Massi D, Franchi A, Borgognoni L, et al. Thin cutaneous malignant melanomas (<or=1.5 mm): identification of risk factors indicative of progression. Cancer. 1999;85:1067–1076
  135. Shaw HM, McCarthy SW, McCarthy WH, et al. Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology. 1989;15:257–265
  136. Barnhill RL, Levy MA. Regressing thin cutaneous malignant melanomas (<or=1.0 mm) are associated with angiogenesis. Am J Pathol. 1993;143:99–104
  137. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869–875
  138. Day CL, Lew RA, Mihm MC, et al. A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg. 1982;195:44–49
  139. Elder DE, Guerry D, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer. 1985;56:413–418
  140. Tuthill RJ, Unger JM, Liu PY, et al. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002;118:504–511
  141. Hakansson A, Gustafsson B, Krysander L, et al. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer. 2001;85:1871–1877
  142. Ladanyi A, Somlai B, Gilde K, et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004;10:521–530
  143. Movassagh M, Spatz A, Davoust J, et al. Selective accumulation of mature DC-Lamp+dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. 2004;64:2192–2198
  144. Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459–1469
  145. Spatz A, Shaw HM, Crotty KA, et al. Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (>5 mm). Histopathology. 1998;33:406–413
  146. Anichini A, Vegetti C, Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother. 2004;53:855–864
  147. Marincola FM, Wang E, Herlyn M, et al. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 2003;24:335–342
  148. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998
  149. Lassau N, Lamuraglia M, Koscielny S, et al. Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer Imaging. 2006;6:24–29
  150. Fallowfield ME, Cook MG. The vascularity of primary cutaneous melanoma. J Pathol. 1991;164:241–244
  151. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993;66:181–196
  152. Vlaykova T, Laurila P, Muhonen T, et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res. 1999;9:59–68
  153. Carlson JA, Ross JS, Slominski A, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol. 2005;52:743–775quiz 75-8
  154. Barnhill RL, Fandrey K, Levy MA, et al. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest. 1992;67:331–337
  155. Vlaykova T, Muhonen T, Hahka-Kemppinen M, et al. Vascularity and prognosis of metastatic melanoma. Int J Cancer. 1997;74:326–329
  156. Srivastava A, Laidler P, Davies RP, et al. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol. 1988;133:419–423
  157. Depasquale I, Thompson WD. Microvessel density for melanoma prognosis. Histopathology. 2005;47:186–194
  158. Rongioletti F, Miracco C, Gambini C, et al. Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4 mm) cutaneous melanoma. A quantitative assay. Am J Dermatopathol. 1996;18:474–477
  159. Neitzel LT, Neitzel CD, Magee KL, et al. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol. 1999;6:70–74
  160. Erhard H, Rietveld FJ, van Altena MC, et al. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 1997;7(Suppl 2):S19–S26
  161. Marcoval J, Moreno A, Graells J, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol. 1997;24:212–218
  162. Straume O, Salvesen HB, Akslen LA. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol. 1999;15:595–599
  163. Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol. 2001;159:223–235
  164. Carnochan P, Briggs JC, Westbury G, et al. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br J Cancer. 1991;64:102–107
  165. Graham CH, Rivers J, Kerbel RS, et al. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol. 1994;145:510–514
  166. Busam KJ, Berwick M, Blessing K, et al. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol. 1995;147:1049–1056
  167. Ilmonen S, Kariniemi AL, Vlaykova T, et al. Prognostic value of tumour vascularity in primary melanoma. Melanoma Res. 1999;9:273–278
  168. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–1491
  169. Lugassy C, Barnhill RL. Angiotropic melanoma and extravascular migratory metastasis: a review. Adv Anat Pathol. 2007;14:195–201
  170. Barnhill RL. The biology of melanoma micrometastases. Recent Results Cancer Res. 2001;158:3–13
  171. Lugassy C, Barnhill RL, Christensen L. Melanoma and extravascular migratory metastasis. J Cutan Pathol. 2000;27:481
  172. Lugassy C, Dickersin GR, Christensen L, et al. Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin. J Cutan Pathol. 1999;26:78–83
  173. Lugassy C, Eyden BP, Christensen L, et al. Angio-tumoral complex in human malignant melanoma characterised by free laminin: ultrastructural and immunohistochemical observations. J Submicrosc Cytol Pathol. 1997;29:19–28
  174. Lugassy C, Shahsafaei A, Bonitz P, et al. Tumor microvessels in melanoma express the beta-2 chain of laminin. Implications for melanoma metastasis. J Cutan Pathol. 1999;26:222–226
  175. Lugassy C, Kleinman HK, Fernandez PM, et al. Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis. J Invest Dermatol. 2002;119:703–704
  176. Barnhill RL, Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology. 2004;36:485–490
  177. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet. 1907;169:996–1003
  178. Gerami P, Shea C, Stone MS. Angiotropism in epidermotropic metastatic melanoma: another clue to the diagnosis. Am J Dermatopathol. 2006;28:429–433
  179. Johnson CS, Ramos-Caro FA, Hassanein AM. Ultra-late erysipeloid angiotropic metastatic malignant melanoma. Int J Dermatol. 2001;40:446–447
  180. Shea CR, Kline MA, Lugo J, et al. Angiotropic metastatic malignant melanoma. Am J Dermatopathol. 1995;17:58–62
  181. Moreno A, Espanol I, Romagosa V. Angiotropic malignant melanoma. Report of two cases. J Cutan Pathol. 1992;19:325–329
  182. Barnhill R, Dy K, Lugassy C. Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis. J Invest Dermatol. 2002;119:705–706
  183. Lugassy C, Vernon SE, Busam K, et al. Angiotropism of human melanoma: studies involving in transit and other cutaneous metastases and the chicken chorioallantoic membrane: implications for extravascular melanoma invasion and metastasis. Am J Dermatopathol. 2006;28:187–193
  184. Setala LP, Kosma VM, Marin S, et al. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer. 1996;74:766–772
  185. Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994;24:41–47
  186. Sondergaard K, Schou G. Therapeutic and clinico-pathological factors in the survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I. A multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol. 1985;408:249–258
  187. Bachaud JM, Shubinski R, Boussin G, et al. Stage I cutaneous malignant melanoma: risk factors of loco-regional recurrence after wide local excision and clinical perspectives. Eur J Surg Oncol. 1992;18:442–448
  188. Gamel JW, George SL, Stanley WE, et al. Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex. Cancer. 1993;72:1219–1223
  189. MacKie RM, Aitchison T, Sirel JM, et al. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer. 1995;71:173–176
  190. Thorn M, Ponten F, Bergstrom R, et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst. 1994;86:761–769
  191. Lugassy C, Eyden BP, Christensen L, et al. Is the angio-tumoral complex in human malignant melanoma a marker of non-hematogenous migration? [abstract]. Melanoma Res. 1997;7:S95
  192. Barnhill RL, Sagebiel RW, Lugassy C. Angiotropic melanoma: report of seven additional cases. [abstract]. J Cutan Pathol. 2000;27:548
  193. Schmoeckel C, Bockelbrink A, Bockelbrink H, et al. Low-and high-risk malignant melanoma-I. Evaluation of clinical and histological prognosticators in 585 cases. Eur J Cancer Clin Oncol. 1983;19:227–235
  194. Arrington JH, Reed RJ, Ichinose H, et al. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol. 1977;1:131–143
  195. MacKie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol. 2000;25:471–475
  196. Swetter SM. Dermatological perspectives of malignant melanoma. Surg Clin North Am 2003;83:77-95, vi.
  197. Weyers W, Euler M, Diaz-Cascajo C, et al. Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer. 1999;86:288–299
  198. Hacene K, Le Doussal V, Brunet M, et al. Prognostic index for clinical Stage I cutaneous malignant melanoma. Cancer Res. 1983;43:2991–2996
  199. Ringborg U, Afzelius LE, Lagerlof B, et al. Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish Melanoma Study Group. Cancer. 1993;71:751–758
  200. Crocetti E, Mangone L, Lo Scocco G, et al. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study. Melanoma Res. 2006;16:429–433
  201. Golger A, Young DS, Ghazarian D, et al. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg. 2007;133:442–447
  202. Kuno Y, Ishihara K, Yamazaki N, et al. Clinical and pathological features of cutaneous malignant melanoma: a retrospective analysis of 124 Japanese patients. Jpn J Clin Oncol. 1996;26:144–151
  203. Giuliano AE, Cochran AJ, Morton DL. Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol. 1982;9:442–447
  204. McGovern VJ, Shaw HM, Milton GW, et al. Cell type and pigment content as prognostic indicators in cutaneous malignant melanoma. In:  Ackerman AB editors. Pathology of malignant melanoma. New York: Masson; 1981;p. 327–332
  205. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med. 1996;125:369–375
  206. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42:731–734
  207. Leon P, Daly JM, Synnestvedt M, et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg. 1991;126:1461–1468
  208. Pol-Rodriquez M, Lee S, Silvers DN, et al. Influence of age on survival in childhood spitzoid melanomas. Cancer. 2007;109:1579–1583
  209. Fabrizi G, Massi G. Spitzoid malignant melanoma in teenagers: an entity with no better prognosis than that of other forms of melanoma. Histopathology. 2001;38:448–453
  210. Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol. 2006;19(Suppl 2):S41–S70
  211. Won JH, Ahn SK, Lee SH, et al. Signet-ring cell melanoma: poor prognostic factor?. Br J Dermatol. 1994;131:135–137
  212. Breier F, Feldmann R, Fellenz C, et al. Primary invasive signet-ring cell melanoma. J Cutan Pathol. 1999;26:533–536
  213. Rutten A, Huschka U, Requena C, et al. Primary cutaneous signet-ring cell melanoma: a clinico-pathologic and immunohistochemical study of two cases. Am J Dermatopathol. 2003;25:418–422
  214. Podnos YD, Jimenez JC, Zainabadi K, et al. Minimal deviation melanoma. Cancer Treat Rev. 2002;28:219–221
  215. Phillips ME, Margolis RJ, Merot Y, et al. The spectrum of minimal deviation melanoma: a clinicopathologic study of 21 cases. Hum Pathol. 1986;17:796–806
  216. Schmoeckel C, Castro CE, Braun-Falco O. Nevoid malignant melanoma. Arch Dermatol Res. 1985;277:362–369
  217. Zembowicz A, McCusker M, Chiarelli C, et al. Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature. Am J Dermatopathol. 2001;23:167–175
  218. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2004;28:1518–1525
  219. Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol. 2005;12:92–102
  220. Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol. 2003;10:403–407
  221. Payne WG, Kearney R, Wells K, et al. Desmoplastic melanoma. Am Surg. 2001;67:1004–1006
  222. Jaroszewski DE, Pockaj BA, DiCaudo DJ, et al. The clinical behavior of desmoplastic melanoma. Am J Surg. 2001;182:590–595
  223. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer. 1998;83:1128–1135
  224. Carlson JA, Dickersin GR, Sober AJ, et al. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995;75:478–494
  225. Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol. 1995;32:717–725
  226. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971;28:914–936
  227. Egbert B, Kempson R, Sagebiel R. Desmoplastic malignant melanoma. A clinicohistopathologic study of 25 cases. Cancer. 1988;62:2033–2041
  228. Baer SC, Schultz D, Synnestvedt M, et al. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer. 1995;76:2242–2247
  229. Day CL, Sober AJ, Lew RA, et al. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer. 1981;47:955–962
  230. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979;86:343–351
  231. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol. 2005;12:207–213
  232. Su LD, Fullen DR, Lowe L, et al. Desmoplastic and neurotropic melanoma. Cancer. 2004;100:598–604
  233. Thelmo MC, Sagebiel RW, Treseler PA, et al. Evaluation of sentinel lymph node status in spindle cell melanomas. J Am Acad Dermatol. 2001;44:451–455
  234. Cummins DL, Esche C, Barrett TL, et al. Lymph node biopsy results for desmoplastic malignant melanoma. Cutis. 2007;79:390–394
  235. Reed RJ. Minimal deviation melanoma. In:  Mihm MC,  Murphy GF,  Kaufman N editor. Pathobiology and recognition of malignant melanoma. Baltimore: Williams and Wilkins; 1988;p. 110–152
  236. Livestro DP, Muzikansky A, Kaine EM, et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol. 2005;23:6739–6746
  237. Shaw HM, Quinn MJ, Scolyer RA, et al. Survival in patients with desmoplastic melanoma. J Clin Oncol. 2006;24:e12;author reply, e3
  238. Reed RJ, Leonard DD. Neurotropic melanoma. A variant of desmoplastic melanoma. Am J Surg Pathol. 1979;3:301–311
  239. Newlin HE, Morris CG, Amdur RJ, et al. Neurotropic melanoma of the head and neck with clinical perineural invasion. Am J Clin Oncol. 2005;28:399–402
  240. Anderson TD, Weber RS, Guerry D, et al. Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy. Head Neck. 2002;24:1068–1071
  241. Madrigal B, Fresno MF, Junquera L, et al. De novo desmoplastic neurotropic melanoma of the lower lip: a neoplasm with ominous behavior. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:452–456
  242. Lin D, Kashani-Sabet M, McCalmont T, et al. Neurotropic melanoma invading the inferior alveolar nerve. J Am Acad Dermatol. 2005;53:S120–S122
  243. Fabre B, Gigaud M, Lamant L, et al. [Trigeminal neuralgia presenting as a deep recurrent desmoplastic neurotropic melanoma of a lentigo maligna]. French. Ann Dermatol Venereol. 2003;130:1044–1046
  244. Byrne PR, Maiman M, Mikhail A, et al. Neurotropic desmoplastic melanoma: a rare vulvar malignancy. Gynecol Oncol. 1995;56:289–293
  245. Barnhill RL, Bolognia JL. Neurotropic melanoma with prominent melanization. J Cutan Pathol. 1995;22:450–459
  246. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 2. The relation of cell type, pigmentation, atypia and mitotic count to histological type and prognosis. Acta Pathol Microbiol Scand [A]. 1978;86A:513–522
  247. Weatherhead SC, Haniffa M, Lawrence CM. Melanomas arising from naevi and de novo melanomas-does origin matter?. Br J Dermatol. 2007;156:72–76
  248. Friedman RJ, Rigel DS, Kopf AW, et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol. 1983;119:455–462
  249. Drunkenmolle E, Marsch W, Lubbe D, et al. Paratumoral epidermal hyperplasia: a novel prognostic factor in thick primary melanoma of the skin?. Am J Dermatopathol. 2005;27:482–488
  250. Kaddu S, Smolle J, Zenahlik P, et al. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res. 2002;12:271–278
  251. Mott RT, Rosenberg A, Livingston S, et al. Melanoma associated with pseudoepitheliomatous hyperplasia: a case series and investigation into the role of epidermal growth factor receptor. J Cutan Pathol. 2002;29:490–497
  252. Hanly AJ, Jorda M, Elgart GW. Cutaneous malignant melanoma associated with extensive pseudoepitheliomatous hyperplasia. Report of a case and discussion of the origin of pseudoepitheliomatous hyperplasia. J Cutan Pathol. 2000;27:153–156
  253. Reis-Filho JS, Gasparetto EL, Schmitt FC, et al. Pseudoepitheliomatous hyperplasia in cutaneous malignant melanoma: a rare and misleading feature. J Cutan Pathol. 2001;28:496–497
  254. Nakayama T, Taback B, Turner R, et al. Molecular clonality of in-transit melanoma metastasis. Am J Pathol. 2001;158:1371–1378
  255. Wong JH, Cagle LA, Kopald KH, et al. Natural history and selective management of in transit melanoma. J Surg Oncol. 1990;44:146–150
  256. Shaikh L, Sagebiel RW, Ferreira CM, et al. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol. 2005;141:739–742
  257. Day CL, Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of “microscopic satellites” in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194:108–112
  258. Harrist TJ, Rigel DS, Day CL, et al. “Microscopic satellites” are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer. 1984;53:2183–2187
  259. Singletary SE, Tucker SL, Boddie AW. Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer. 1988;61:1437–1440
  260. Cascinelli N, Bufalino R, Marolda R, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol. 1986;12:175–180
  261. Sutherland CM, Mather FJ, Krementz ET. Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet. 1987;164:111–118

PII: S0738-081X(08)00183-1

doi: 10.1016/j.clindermatol.2008.09.006

Clinics in Dermatology
Volume 27, Issue 1 , Pages 53-74 , January 2009

Article Tools